News & Updates

Show Multimedia Only

Unveiling ceramide science and multivesicular emulsion technology in atopic dermatitis management

01 Aug 2024

At the recent hybrid launch event, ‘Unveiling Innovative Ceramide Science’, jointly organized by L’Oréal Dermatological Beauty (LDB), Malaysian Medical Association, Dermatological Society of Malaysia, Dermatological Society of Singapore and MIMS Medica, three distinguished speakers shared their perspectives on the current landscape of atopic dermatitis (AD) management and offered insights on the role of ceramides and multivesicular emulsion (MVE) technology in the management of AD. The event was chaired and moderated by Dato' Dr Noor Zalmy Azizan, a Senior Consultant Dermatologist at Central Dermatology Specialist Clinic, Malaysia.

Unveiling ceramide science and multivesicular emulsion technology in atopic dermatitis management

01 Aug 2024

Revolutionary molecule improves potency of skincare regimen for hyperpigmentation disorders

01 Aug 2024

A sponsored symposium by La Roche-Posay saw two leading experts discuss hyperpigmentation disorders in terms of its global impact on patients and social stigma, and the use of an innovative molecule, Melasyl TM, to treat patients. A serum containing Melasyl TM was launched during the symposium.

Revolutionary molecule improves potency of skincare regimen for hyperpigmentation disorders

01 Aug 2024

DOAC for improved patient outcomes in atrial fibrillation

01 Aug 2024

A panel of eminent cardiologists and a neurologist discusses the role of DOAC in patients with atrial fibrillation (AF) at a Boehringer-Ingelheim sponsored symposium during the recent National Heart Association of Malaysia Congress 2024.

DOAC for improved patient outcomes in atrial fibrillation

01 Aug 2024

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

In the treatment of patients with anogenital lichen sclerosus, the use of hydroxychloroquine appears to induce favourable response rates with low incidence of adverse effects, as shown in a retrospective study.

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

31 Jul 2024 by

In the treatment of genitourinary syndrome of menopause (GSM), the nonhormone alternative vaginal hyaluronic acid is equally efficacious as the treatment standard vaginal oestrogen, while being well-tolerated, as shown in a pilot study.

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

31 Jul 2024

Flap reconstruction prolongs treatment time in patients with oral cavity, larynx cancers

31 Jul 2024

In patients with carcinoma of the oral cavity and larynx treated with surgery and adjuvant radiotherapy, use of flap reconstructions led to a much longer overall treatment time, according to results of a study.

Flap reconstruction prolongs treatment time in patients with oral cavity, larynx cancers

31 Jul 2024

Is it unsafe to use GLP-1 RAs in early pregnancy?

31 Jul 2024 by

Exposure to GLP-1 receptor agonist (RA) treatment during early pregnancy does not appear to increase the risk of complications in pregnant women, as shown in a study presented at ESHRE 2024.

Is it unsafe to use GLP-1 RAs in early pregnancy?

31 Jul 2024

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

31 Jul 2024

Treatment with antiplatelet medications and age are some of the factors associated with the occurrence of radiation proctitis in patients with locally advanced cervical cancer treated by chemoradiation, a recent study has shown.

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

31 Jul 2024

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

31 Jul 2024 by

In the 3-year updated analysis of the phase III TOPAZ-1 study, the combination of durvalumab and gemcitabine-cisplatin (GC) chemotherapy continues to deliver an overall survival (OS) benefit in individuals with biliary tract cancer (BTC).

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

31 Jul 2024

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

31 Jul 2024

A more selective risk-based approach to an enoxaparin thromboprophylaxis protocol appears to reduce the incidence of wound hematomas without increasing the rates of postpartum venous thromboembolism (VTE), as shown in a retrospective study.

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

31 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Unveiling ceramide science and multivesicular emulsion technology in atopic dermatitis management

Unveiling ceramide science and multivesicular emulsion technology in atopic dermatitis management

Revolutionary molecule improves potency of skincare regimen for hyperpigmentation disorders

Revolutionary molecule improves potency of skincare regimen for hyperpigmentation disorders

DOAC for improved patient outcomes in atrial fibrillation

DOAC for improved patient outcomes in atrial fibrillation

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

Vaginal hyaluronic acid matches up to oestrogen for relieving GSM

Flap reconstruction prolongs treatment time in patients with oral cavity, larynx cancers

Flap reconstruction prolongs treatment time in patients with oral cavity, larynx cancers

Is it unsafe to use GLP-1 RAs in early pregnancy?

Is it unsafe to use GLP-1 RAs in early pregnancy?

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

Anticoagulant use, older age predict radiation proctitis in chemoradiation-treated cervical cancer

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

TOPAZ-1 3-year data reflect long-term survival benefit with durvalumab-chemo in BTC

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection

Selective enoxaparin protocol lowers hematoma rates without compromising VTE protection